Drug intelligence / Profile preview

autologous serum tears

Development stage
Phase 3
Administration
Ophthalmic
01

Overview

Autologous serum tears (AST) are a biological product derived from a patient's own blood, processed to create eye drops that resemble natural tears. They contain essential components such as epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), vitamins, and nutrients. These components support epithelial cell homeostasis, growth, and migration, and promote corneal nerve regeneration. AST are primarily used as a therapeutic alternative for severe dry eye disease (DED), especially in cases refractory to conventional treatments or secondary to systemic conditions like Sjögren's syndrome and ocular graft-versus-host disease (GvHD), as well as ocular pathologies such as neurotrophic keratitis, chemical burns, and ocular cicatricial pemphigoid. They are often considered a third-line treatment option for severe DED.

Other names
ASTautologous serum eye drops
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TGFBR (TGF-beta receptor)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on autologous serum tears.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous serum tears.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call